Recognized as a Worldwide Leader in Oncology & Immuno-Oncology Clinical Development

Our 20+ years of successful global oncology trials is the direct result of our unique, purpose-built blend of proprietary technologies, logistical expertise, and focus on an experienced workforce, especially for clinical research associate (CRA) roles.

Our biostatistics team designs trials that make the most effective and efficient use of biomarker assays while our innovative scientists combine platform technologies and state-of-the-art data science to maximize what you can learn from each data point.

Recognized as a Worldwide Leader in Oncology & Immuno-Oncology Clinical Development

Our 20+ years of successful global oncology trials is the direct result of our unique, purpose-built blend of proprietary technologies, logistical expertise, and focus on an experienced workforce, especially for clinical research associate (CRA) roles.

Our biostatistics team designs trials that make the most effective and efficient use of biomarker assays while our innovative scientists combine platform technologies and state-of-the-art data science to maximize what you can learn from each data point.

Our proprietary technologies solve oncology & immuno-oncology clinical study challenges

Part of what makes Precision unique is our history of scientific innovation. Not only do we combine state-of-the-art approaches to maximize the information each tumor provides, we create proprietary technologies that solve oncology & immuno-oncology clinical study challenges:

  • Epiontis ID – an immunophenotyping technology that is a cost-effective and easier-to-implement alternative to immunophenotyping by flow cytometry. Learn about Epiontis ID
  • ApoStream – an antibody-free method for capturing and enriching for circulating tumor cells (CTCs) as well as other rare cell types from liquid biopsies. Learn about ApoStream
  • QuartzBio – a computational, informatics, and sample inventory management platform that harmonizes clinical and biomarker data for real-time decision-making.
    • Combines multi-omics biomarker data
    • Includes flow cytometry analysis capabilities

Learn about QuartzBio >

Our specialty lab capabilities enable a wide range of biomarker assays

We specialize in developing workflows that maximize what you can learn from each tumor sample, including:

  • Multiplex IHC and multiplex immunofluorescence (up to 9 colors) for immune monitoring, such as detecting T cell infiltration and other spatial analyses
  • Flow cytometry for immune monitoring, receptor occupancy measurements, phospho flow cytometry, and other oncology and immuno-oncology applications
  • Other immune monitoring approaches like our proprietary Epiontis ID platform
  • Genomics approaches for gene expression profiling, SNP detection, copy number variation detection, and more
  • Liquid biopsy technologies, such as our proprietary ApoStream platform for CTC capture and enrichment

Learn more about our Specialty Lab capabilities >

Quantitative multiplex immunofluorescence: A powerful tool for tumor profiling

We drive preclinical through to Phase III studies with deep expertise and broad experience

Our experience covers everything from biomarker assay development and pre-clinical computational modeling through to Phase III studies and regulatory submission, with services that include the full breadth of clinical activities.

Small molecule, protein antibody therapies, cell gene therapies
  • Kinase inhibitors
  • Cytokine and chemokines
  • Monoclonal and Bifunctional antibodies
  • Combinations with chemotherapy, radiotherapy, immunotherapy
  • Oncolytic viruses
  • Apoptosis modulators
  • Hormonal modulators
  • Metabolic modulators
  • Immunotherapy, immunomodulatory agents
  • Proteosome inhibitors
  • DNA repair modulators
  • Epigenetic modulators
  • Diagnostic targeted radioisotopes and imaging agents
  • Targeted therapy
  • Personalized vaccines
  • Tumor-targeting strategies
  • Anti-angiogenic agents
  • Vascular disrupting agents
  • Therapeutic targeted radioisotopes
  • Peptides
  • ADCC-inducing or modulating agents
  • Therapeutic and diagnostic antibodies
  • MonoCancer stem cell modulators
Novel cell-based immune therapies
  • Autologous Cells
  • Allogeneic Cells
  • Molecularly Altered/Edited Cells including CRISPR/edited cells
  • Hematopoietic stem cell transplantation
Multiple targets and approaches
  • Diagnostics – Imaging, Companion
  • Research Labs, Liquid and Cellular Biomarkers
  • Protein Targets
  • RNA Targets
  • DNA Targets
  • Multiple-targeted Pathway Agents
  • Cancer Surface Epitope Inhibition, Activation, Internalization
  • Co-stimluation activation, safety and efficacy
  • Apheresis, logistics, details
  • Small molecule to large molecule in human immune stimulation

Clinical data science to support oncology therapeutic development

Oncology and I/O are logistically complex and data rich areas of development given the breadth and depth of biomarkers involved. Precision’s unique Data Sciences capabilities empower Sponsors

Proactive planning to optimize the use of biomarkers in oncology clinical trials

We have experience across a broad range of oncology & immuno-oncology indications

Hematologic
  • AML / Leukemia
  • Lymphoma
  • Multiple myeloma
  • Myelofibrosis
  • Other hematological
Other
  • Cancer Support / Cancer related
  • Mixed (hematological and solid)
  • Paediatric
  • Companion Diagnostics
Solid Tumors
  • Brain cancers
  • Pancreatic cancer
  • Lung cancers
  • Genitourinary cancers
  • Breast cancers
  • Gynecological malignancies
  • Gastrointestinal cancers
  • Hepatobiliary cancers
  • Head and neck cancers
  • Neuro-oncologic cancers
  • Skin malignancies
  • Endocrine system cancers

We combine global clinical trial excellence with biomarker-driven science

Personalization
  • Biomarker-driven match of the right patient with the right drug
  • Precision’s team operates as an extension of the Sponsor’s team, with unified goals and transparency
  • Highly experienced oncology CRA workforce with proven stability and devoted focus
Specialization
  • Dedicated specialists in oncology and immuno-oncology
  • 20+ years of conducting oncology clinical trials
  • 350+ oncology studies
  • A dedicated, international network of proprietary oncology sites (OSN)
Biomarker science at scale
  • Customized biomarker solutions integrated with global clinical trial execution
  • Biomarker data-driven management and proprietary QuartzBio technology platform
  • Rigorous logistical expertise and strength

Customized oncology and immuno-oncology solutions

Discover how our oncology & immuno-oncology therapeutic area expertise can advance your clinical development program

Discover how our oncology & immuno-oncology therapeutic area expertise can advance your clinical development program

Services supporting clinical development of oncology & immuno-oncology therapeutics

Immune Monitoring

Leverage sophisticated immune monitoring approaches, including flow, Epiontis ID immune cell phenotyping, and cytokine profiling, to characterize the immune cells in your samples and understand their impact on patient biology.

Tissue & Liquid Biopsy

Obtain a detailed molecular view into patient biology with a range of tissue and liquid biopsy technologies, including our proprietary ApoStream platform which can isolate and enrich circulating tumor cells for downstream analysis.

Oncology Clinical Trials

Through 20+ years running successful oncology trials, we’ve developed a unique blend of proprietary technologies, flexible processes, and creative problem solving abilities that advance even the most challenging clinical development programs.

Explore other areas of expertise